PAR-24-117: The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 12, 2025.
From the official notice on Grants.gov, last changed July 10, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeK22
- Clinical trialsIndependent clinical trial optional
- Funded byNCI
- Median yearly award$191,722
- Typical project length3 years
- K22, Career Transition Award. Support for moving from a postdoctoral position to an independent research job. Other open K22 notices.
Projects funded under PAR-24-117 were run by National Cancer Institute (NCI, 20 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-24-117 in the NIH Guide.
Key dates
| Posted | February 9, 2024 |
|---|---|
| Deadline | November 12, 2025 |
| Archived by Grants.gov | December 12, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.
Funded under PAR-24-117 so far
NIH funded 20 projects under PAR-24-117 in fiscal 2025 to 2026, at 17 institutions. The median yearly award was $191,722.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Targeting Mitochondrial Fusion in Colorectal Cancer | Purdue University | 2026 | $190,944 |
| Targeting the RNA helicase eIF4A to enhance anti-tumor immunity | Baylor College of Medicine | 2026 | $191,681 |
| Modeling Enhancer Hijacking in Cancer via Genome Engineering and Single-Cell Sequencing | University of Texas HLTH Sci Ctr Houston | 2026 | $194,914 |
| Targeting Glycerol Metabolism in anti-Tumor Immunity | University of Chicago | 2026 | $185,760 |
| Secreted peptides as biomarkers and effectors of neuroendocrine transformation | University of TX MD Anderson Can Ctr | 2026 | $192,224 |
| Sphingolipid-guided stratification and therapeutic opportunities in Acute Myeloid Leukemia | University of Virginia | 2026 | $192,887 |
| Elucidating the Mechanisms of MRE11-Mediated cGAS Activation in DNA Sensing: Mechanisms of cGAS Activation | State University New York Stony Brook | 2026 | $223,938 |
| Mutation specific pan-KRAS inhibitor signaling responses and anti-tumor effect | Ohio State University | 2026 | $188,351 |
Who has won Cancer Research Manpower grants before
From fiscal 2021 to 2025, Cancer Research Manpower (93.398) awarded $1.0 billion across 2,913 grant awards, an average of $359,612 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Sloan-Kettering Institute for Cancer Research | New York | 92 | $52.8 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 100 | $38.4 million |
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 65 | $35.5 million |
| The General Hospital Corporation | Massachusetts | 58 | $35.4 million |
| The Johns Hopkins University | Maryland | 69 | $33.7 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-24-117 still open?
No. It closed on November 12, 2025.
Who can apply for The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)?
Closed November 12, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-24-117?
NIH RePORTER lists 20 projects funded under PAR-24-117 in fiscal 2025 to 2026, at 17 institutions. The most were at Purdue University, University of Virginia, Utah State Higher Education System--University of Utah.
Who has won Cancer Research Manpower grants before?
The largest recipients over five fiscal years were Sloan-Kettering Institute for Cancer Research, Dana-Farber Cancer Institute, Inc., The Univeristy of Texas M.D. Anderson Cancer Center. The program made 2,913 awards worth $1.0 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)
- NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)
- Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)
- Career Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
- NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed)